First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN

被引：0
|
作者：
Hou, X. [1 ]
Zhou, C. [2 ]
Wu, G. [3 ]
Lin, W. [4 ]
Xie, Z.
Zhang, H. [2 ,5 ,6 ]
Yi, J. [7 ]
Peng, Z. [8 ]
Yin, L. [8 ]
Ma, C. [8 ]
Chen, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Meizhou Peoples Hosp, Huangtang Hosp, Meizhou, Peoples R China
[4] Shantou Univ, Canc Hosp, Med Coll, Shantou, Peoples R China
[5] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China
[6] Guangzhou Univ Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China
[7] Guangzhou Red Cross Hosp, Guangzhou, Peoples R China
[8] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-squamous non-small-cell lung cancer; Brain metastases; Immunochemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-04
引用
收藏
页码：S318 / S318
页数：1
相关论文
共 50 条
  • [41] MO19390 (SAiL): safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)
    Griesinger, Frank
    Pavlakis, Nick
    Garrido, Pilar
    Dansin, Eric E.
    Crino, Lucio
    Thatcher, Nicholas
    Laskin, Janessa
    Zhou, Caicun
    Kohlhaeufl, Martin J.
    Tsai, Chun-Ming
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S359 - S360
  • [42] Safety and activity of second-line durvalumab plus tremelimumab in non-squamous advanced NSCLC
    Chaft, Jamie
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Le Moulec, Sylvestre
    Cho, Eun Kyung
    Papadimitrakopoulou, Vassiliki
    Garon, Edward
    Lee, Sylvia
    Aix, Santiago Ponce
    Ma, Patrick C.
    Otterson, Gregory
    Narwal, Rajesh
    Gao, Guozhi
    McDevitt, Jennifer
    Englert, Judson
    Antonia, Scott
    CANCER RESEARCH, 2018, 78 (13)
  • [43] RATIONALE-304 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo for locally advanced or metastatic non-squamous (NSQ) NSCLC
    Ma, Z.
    Yu, Y.
    Yu, X.
    Li, X.
    Cui, J.
    Wang, D.
    Wang, X.
    Wu, J.
    Huang, D.
    Li, G.
    Zhao, N.
    Liang, L.
    Song, M.
    Lu, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1637
  • [44] A Phase II Trial of Tiragolumab with Carboplatin, Pemetrexed, And Atezolizumab in Non-Squamous NSCLC and Brain Metastases
    Schluger, B.
    Burns, T. F.
    Wang, H.
    Petro, D. P.
    Ohr, J.
    Burton, S. A.
    McCall, N.
    Choi, S.
    Abdullah, K. G.
    Niranjan, A.
    Hadjipanayis, C. G.
    Villaruz, L. C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S393 - S394
  • [45] Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
    Andric, Zoran
    Galffy, Gabriella
    Dols, Manuel Cobo
    Szima, Barna
    Stojanovic, Goran
    Petrovic, Marina
    Felip, Enriqueta
    Baz, David Vicente
    Aix, Santiago Ponce
    Juan-Vidal, Oscar
    Szalai, Zsuzsanna
    Losonczy, Gyorgy
    Blanco, Antonio Calles
    Bernabe, Reyes
    Ledo, Gema Garcia
    Hernandez, Andres Aguilar
    Duecker, Klaus
    Zhou, Dongli
    Schroeder, Andreas
    Guezel, Guelseren
    Ciardiello, Fortunato
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
  • [46] First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
    Provencio-pulla, M.
    Ortega, A. L.
    Coves, J.
    Franco, F.
    Marse, R.
    Domine, M.
    Guirado, M.
    Carcereny, E.
    Fernandez, N.
    Martinez, E.
    Blanco, R.
    Leon, L.
    Sanchez, J. M.
    Sullivan, I.
    Cobo, M.
    Sanchez, A.
    Massuti, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S123 - S124
  • [47] Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [48] Effects of diagnostic method and surgery on safety of first-line bevacizumab plus chemotherapy in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)
    Tsai, C.
    Thatcher, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S379
  • [50] Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
    J. De Castro
    J. L. González-Larriba
    S. Vázquez
    B. Massutí
    J. M. Sanchez-Torres
    M. Dómine
    P. Garrido
    A. Calles
    A. Artal
    R. Collado
    R. García
    M. Sereno
    M. Majem
    J. A. Macías
    O. Juan
    J. Gómez-Codina
    B. Hernández
    M. Lázaro
    A. L. Ortega
    M. Cobo
    J. M. Trigo
    E. Carcereny
    C. Rolfo
    S. Macia
    J. Muñoz
    P. Diz
    M. Méndez
    F. Rosillo
    L. Paz-Ares
    J. V. Cardona
    D. Isla
    Clinical and Translational Oncology, 2017, 19 : 219 - 226
12345